David G. Mcleod

David G. Mcleod's AcademicInfluence.com Rankings

David G. Mcleod

Philosophy

#8343

World Rank

#11700

Historical Rank

Logic

#5375

World Rank

#6769

Historical Rank

philosophy Degrees

David G. Mcleod

Biology

#11277

World Rank

#14662

Historical Rank

Endocrinology

#164

World Rank

#176

Historical Rank

Biochemistry

#1851

World Rank

#1991

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

David G. Mcleod's Degrees

Doctorate Medicine Harvard University
PhD Biochemistry Stanford University

Why Is David G. Mcleod Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David G. Mcleod's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. (1989) (1439)
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. (1998) (870)
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. (2004) (410)
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. (1994) (407)
Age-specific reference ranges for serum prostate-specific antigen in black men. (1996) (380)
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. (2000) (341)
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. (2002) (328)
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. (2007) (311)
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer (1995) (295)
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. (2003) (289)
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. (2015) (279)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (2006) (275)
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer (2006) (273)
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation (2008) (262)
Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. (1995) (242)
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification (2010) (239)
Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. (1996) (236)
Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. (2000) (232)
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. (2002) (208)
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. (2005) (207)
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. (2004) (206)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (2005) (205)
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. (2008) (189)
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. (2000) (186)
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. (1996) (184)
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. (2004) (171)
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. (1996) (166)
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone (1983) (162)
Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer (2008) (160)
Hormonal therapy: historical perspective to future directions. (2003) (155)
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence (2010) (153)
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. (2000) (147)
Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. (1996) (141)
Diagnostic potential of serum proteomic patterns in prostate cancer. (2003) (137)
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells (2002) (133)
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. (1995) (125)
A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group (2001) (125)
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. (2009) (123)
PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. (2003) (117)
Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. (1992) (112)
Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer (2008) (112)
Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes (2001) (110)
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. (2008) (109)
Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years (2010) (108)
p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. (1995) (107)
Chronic orchialgia in the pain prone patient: the clinical perspective. (1991) (105)
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. (2002) (104)
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. (2005) (103)
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. (1991) (103)
Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. (2002) (101)
Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. (2001) (96)
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. (1994) (94)
Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. (1998) (90)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens (2018) (89)
Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database (2011) (89)
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. (1999) (87)
Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival (2006) (87)
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma (2000) (86)
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. (2003) (86)
Gynecomastia in patients with prostate cancer: a review of treatment options. (2000) (85)
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss (2002) (81)
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. (2011) (80)
Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. (1994) (80)
Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy (1997) (79)
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. (1983) (77)
Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. (2003) (77)
Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. (2006) (76)
Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. (2001) (75)
How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. (1997) (75)
Leuprolide With and Without Flutamide in Advanced Prostate Cancer (1990) (75)
A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells* (2008) (74)
Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. (2012) (73)
The bicalutamide Early Prostate Cancer Program. Demography. (2001) (72)
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. (2003) (71)
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. (2005) (71)
Risk factors for perineal seeding of prostate cancer after needle biopsy. (1989) (70)
Introduction to artificial neural networks for physicians: Taking the lid off the black box (2001) (68)
Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. (1998) (68)
Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. (2007) (68)
The role of retroperitoneal lymphadenectomy in mature teratoma of the testis. (1997) (67)
Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men (2013) (67)
Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer (2010) (63)
Intracranial metastases in prostate cancer (1984) (62)
A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men (2015) (62)
Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. (1996) (61)
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. (1995) (60)
Allelic loss on chromosome 6Q in primary prostate cancer (1999) (59)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (59)
Negative pressure devices in the explanted penile prosthesis population. (1989) (59)
Clinical potential of the ERG oncoprotein in prostate cancer (2012) (58)
Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector (1997) (57)
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. (1998) (57)
The burden of prostate cancer in Asian nations (2012) (55)
Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression (2011) (54)
A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. (1983) (54)
The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma (2009) (54)
Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era (2001) (53)
Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients (2005) (53)
The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? (1996) (52)
Prostate cancer in men less than the age of 50: a comparison of race and outcomes. (2011) (52)
Silencing of lactotransferrin expression by methylation in prostate cancer progression (2007) (52)
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. (2006) (52)
Prognostic significance of DNA ploidy in carcinoma of prostate. (1989) (51)
Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. (1999) (50)
Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. (2002) (50)
Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers? (1996) (49)
Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. (1999) (48)
A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer (2015) (48)
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer (2019) (47)
Quantitative expression profile of PSGR in prostate cancer (2006) (47)
Antiandrogenic drugs (1993) (45)
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. (1995) (44)
ERG oncogene modulates prostaglandin signaling in prostate cancer cells (2011) (43)
Effect of exogenous testosterone replacement on prostate‐specific antigen and prostate‐specific membrane antigen levels in hypogonadal men (1995) (43)
Use of Glycosylated Hemoglobin to Identify Diabetics at High Risk for Penile Periprosthetic Infections (1992) (43)
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. (2003) (43)
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. (2002) (42)
A novel human cancer culture model for the study of prostate cancer (2001) (42)
Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up. (2001) (42)
Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. (1995) (42)
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. (2014) (40)
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. (2005) (39)
Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy (2010) (39)
Anaplastic seminoma. An analysis of 77 patients (1979) (38)
Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. (2008) (38)
A comparison of testicular tumors in black and white patients. (1981) (37)
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. (2003) (37)
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. (1998) (37)
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. (2006) (37)
Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adknocarcinoma of the prostate (CAP): Results of NCI ntergroup study 0105 (SWOG and ECOG) (1997) (36)
Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. (1994) (36)
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients (1997) (35)
Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens (1997) (35)
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. (2018) (35)
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. (2004) (34)
Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. (2002) (34)
Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. (1999) (34)
Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients (2002) (34)
Mutations of the p16 gene product are rare in prostate cancer (1997) (33)
Improvements in pathologic staging for African‐American men undergoing radical retropubic prostatectomy during the prostate specific antigen era (2001) (33)
Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer* (2005) (33)
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. (1997) (33)
Management of Disseminated Prostate Cancer (2003) (33)
Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in CT2B prostate cancer -24 month results (1997) (32)
Radical prostatectomy with pelvic lymphadenectomy: observations on the accuracy of staging with lymph node frozen sections. (1981) (32)
The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. (1997) (32)
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer (2020) (32)
Combined androgen blockade: the gold standard for metastatic prostate cancer. (1997) (31)
Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer (2006) (31)
Candida albicans corpora abscess following penile prosthesis placement. (1988) (30)
Acute urinary retention associated with prostatic carcinoma. (1989) (30)
The clinical significance of unconventional orchiectomy approaches in testicular cancer: a report from the Testicular Cancer Intergroup Study. (1988) (30)
Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. (2007) (30)
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN (2015) (29)
Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells (2017) (28)
Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens (2008) (28)
High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial (2018) (28)
Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment. (2010) (27)
Clinicopathological behavior of single focus prostate adenocarcinoma. (2009) (27)
Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. (2008) (27)
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. (2013) (27)
Silent renal obstruction with severe functional loss after extracorporeal shock wave lithotripsy: a report of 2 cases. (1987) (27)
Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort (2011) (26)
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. (2003) (26)
Molecular implications of the antiandrogen withdrawal syndrome. (1995) (26)
Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival (2008) (26)
Time to an undetectable prostate‐specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer‐specific mortality (2007) (26)
Prostate cancer marker panel with single cell sensitivity in urine (2015) (26)
Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. (2013) (25)
Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. (1998) (25)
Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status (2009) (25)
Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection. (1991) (25)
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. (2003) (25)
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. (1995) (24)
Evaluation of ERG responsive proteome in prostate cancer (2014) (24)
Efficacy of radiographic chest imaging in patients with testicular cancer. (1994) (23)
Predominance of ERG-negative high-grade prostate cancers in African American men. (2014) (23)
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods (2015) (23)
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer (2014) (22)
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer (2016) (22)
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. (2009) (22)
p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein (2003) (21)
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. (2004) (21)
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues (1999) (21)
The design and implementation of a multidisciplinary prostate cancer clinic. (2007) (21)
Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. (2007) (21)
External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence (2004) (20)
Controversies in the treatment of metastatic prostate cancer (1992) (20)
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. (1990) (20)
Experience with the AMS 600 malleable penile prosthesis. (1986) (20)
Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. (1991) (20)
Prostate‐specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer (2007) (19)
Combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long‐term follow‐up (2009) (19)
Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA (1996) (18)
Cost-effective uroflowmetry in men. (1985) (18)
Tolerability of Antiandrogens in the Treatment of Prostate Cancer (2004) (18)
Sarcoidosis of the prostate (2006) (17)
The use of flutamide in hormone‐refractory metastatic prostate cancer (1990) (17)
Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India (2013) (17)
Lymphovascular invasion in prostate cancer (2006) (16)
Indium-111-capromab pendetide scans: an important test relevant to clinical decision making. (2001) (16)
A case report: duplicated vena cava with right retrocaval ureter and ureteral tumor. (1978) (16)
Leiomyosarcoma of the inferior vena cava presenting as a suprarenal mass. (1983) (16)
The effective management of biochemical recurrence in patients with prostate cancer. (2005) (15)
Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression (2011) (15)
Colorectal Prostate Skin Cancer Screening Among Hispanic White Non-Hispanic Men 2000–2005 (2011) (14)
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate (1983) (14)
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. (2011) (14)
Radiation therapy: a primary treatment modality for seminoma. (1980) (14)
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag (2016) (14)
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? (2006) (14)
Bilateral organ-limited amyloidosis of the distal ureter associated with osseous metaplasia and radiographic calcification. (1988) (13)
Comparative study of the clinical efficacy of two dosing regimens of flutamide. (1999) (13)
HORMONAL TREATMENT BEFORE RADICAL PROSTATECTOMY: A 3-YEAR FOLLOWUP (1998) (13)
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. (2017) (12)
Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. (2004) (12)
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? (2008) (12)
Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005. (2010) (11)
Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. (2005) (11)
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. (2002) (11)
ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor (AR) as a Consequence of Fusion of ERG with AR Regulated Gene Promoters (2010) (11)
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. (2004) (11)
Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. (1998) (11)
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer (2014) (10)
A novel neoplastic primary tumor-derived human prostate epithelial cell line. (2003) (10)
224 Response to second-line hormonal therapy following progression on bicalutamide (‘casodex’) 150 MG monotherapy (2004) (10)
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. (2010) (10)
ERG Expression Levels in Prostate Tumors Reflect Functional Status ofthe Androgen Receptor (AR) as a Consequence of Fusion of ERG with ARRegulated Gene Promoters (2010) (10)
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence (2019) (10)
Success and failure of single-modality treatment for early prostate cancer. (2004) (9)
1184: How Long can Radical Prostatectomy (RP) Safely be Delayed? CPDR'S Experiences From 3324 Cases (2004) (9)
Emerging role of adjuvant hormonal therapy. (2002) (9)
Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T trials in advanced prostate cancer. (2011) (9)
A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer (2015) (9)
1013: Prostate-Specific Antigen Levels as a Predictor of Positive Bone Scans During Follow-Up After Standard Care for Prostate Cancer: Data from the Bicalutamide Early Prostate Cancer Program (2005) (9)
A Comparison of Leuprolide with Flutamide and Leuprolide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate, Phase III, Intergroup Study-0036 (1987) (9)
Prostatic trauma and release of acid phosphatase. Radioimmunochemical and enzymatic comparison. (1980) (8)
Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. (1989) (8)
Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover (2003) (8)
Radiation therapy for nonseminomatous germ cell tumors of the testis: a reappraisal. (1981) (8)
Postoperative myocardial infarction after radical cystoprostatectomy masked by patient-controlled analgesia. (1995) (8)
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. (2014) (8)
Thymic hyperplasia in newly diagnosed testicular germ cell tumors. (1994) (8)
Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. (1996) (8)
The emergence of radioimmunoscintigraphy for prostate cancer. (2006) (8)
ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS (1999) (8)
Prognostic features of Annexin A2 expression in prostate cancer. (2020) (8)
An assessment of the virtual conversations method for prostate cancer patient education. (2007) (7)
Defining the role of antiandrogens in the treatment of prostate cancer. (1996) (7)
Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology. (2010) (7)
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center (2002) (7)
Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man. (1994) (7)
OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL‐T: PRELIMINARY DATA FROM THE PROCEED REGISTRY: PD24‐12 (2017) (7)
Primary malignant melanoma of the scrotum (2006) (6)
National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. (1991) (6)
Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. (2016) (6)
3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation. (2000) (6)
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. (2019) (6)
180 Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Updated analysis at a median 5.4 years' follow-up (2004) (6)
Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy (2002) (6)
Bicalutamide (“Casodex”) 150 mg as adjuvant to radiotherapy in localized or locally advanced prostate cancer (2001) (5)
The liver scan in urologic oncology. (1980) (5)
Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low‐volume tumors (2010) (5)
Malpractice claims for urogenital injuries. (1988) (5)
Controversies in the treatment of prostate cancer with maximal androgen deprivation. (1995) (5)
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression (2022) (4)
Delineation of TMPRSS 2-ERG SpliceVariants in Prostate Cancer (2008) (4)
Patient selection for experimental adjuvant therapy after radical prostatectomy. (1996) (4)
Low-velocity gunshot injury to ureter. (1978) (4)
Correction: Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy (2010) (4)
Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T). (2017) (4)
Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme (2002) (3)
Modification of the surgical technique in radical cystectomy. (1996) (3)
Hepatic subcapsular extension of pelvic lymphocele after radical retropubic prostatectomy. (1998) (3)
182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up (2004) (3)
Original Articles PRETREATMENT TOTAL TESTOSTERONE LEVEL PREDICTS PATHOLOGICAL STAGE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY (2003) (3)
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. (2021) (3)
Words of wisdom. Re: Antibody-based detection of ERG rearrangement-positive prostate cancer. (2011) (3)
Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (3)
Is the efficacy of hormonal therapy affected by lymph node status new data from the bicalutamide EPC programme (2002) (3)
The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years. (2006) (3)
MP39-18 HIGHER FREQUENCY OF GERMLINE BRCA1 AND BRCA2 MUTATIONS IN AFRICAN AMERICAN PROSTATE CANCER (2016) (3)
953 SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (2012) (3)
Critical appraisal of routine supraclavicular lymph node biopsy in staging of testicular tumors. (1979) (2)
Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients (2008) (2)
Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. (2017) (2)
Prostate cancer in men under the age of 50: A comparison of race and outcomes. (2010) (2)
Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. (2018) (2)
Epidemiology of prostate cancer, its treatment and outcome: introduction of the Department of Defense Center for Prostate Disease Research (DOD-CPDR) multicenter prostate cancer database with 307,931 records on 13,878 men (2002) (2)
810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up) (2004) (2)
1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up (2004) (2)
Abstract 3296: Tumor antigens Fetuin-A and Secreted Protein Acidic and Rich in Cysteine (SPARC) Autoantibodies as diagnostic and prognostic biomarkers in prostate cancer (2019) (2)
Ureteral carcinoma presenting as a complex pelvic mass in a post menopausal patient. (1998) (2)
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry. (2018) (2)
EDITORIAL: PROSTATE CANCER DIAGNOSIS (1995) (2)
Investigating 3D tumor distribution for optimized diagnosis of prostate cancer. (2000) (2)
523: Prostate-Specific Antigen Velocity and the Odds of Identifying Prostate Cancer at Biopsy (2006) (2)
Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present. (2009) (2)
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia (2021) (2)
LBA22A PROSPECTIVELY-DESIGNED STUDY TO DETERMINE THE ASSOCIATION OF A 17-GENE GENOMIC PROSTATE SCORE WITH RECURRENCE FOLLOWING SURGERY FOR LOCALISED PROSTATE CANCER (PCA) (2014) (2)
An analysis of watchful waiting for prostate cancer and factors to predict secondary treatment (2003) (2)
Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers (2021) (2)
Abstract 1183: Structure-activity studies and biological evaluations of ERGi-USU, a highly selective inhibitor for ERG-positive prostate cancer cells (2017) (2)
Treatment of clinically organ confined prostate cancer. (1999) (1)
UP-02.194 Improved Detection of Prostate Cancer by the Combined Application of ERG and AMACR Immunohistochemical Stainings in Prostate Biopsy Specimens (2011) (1)
Storm over screening for prostate specific antigen. Give men facts on prostate cancer. (2002) (1)
1125: Mapping of TMPRSS2-ERG Fusion in Multi-Focal Prostate Cancer (2007) (1)
Clinical predictors of response in metastatic germ cell tumors (1988) (1)
Editorial: Prostate Cancer (1995) (1)
Abstract 5277: ERG-based stratification of prostate cancer highlights ethnicity associated biological differences (2015) (1)
Phase IClinical Trial of a HER-2 / neu Peptide ( E 75 ) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients (2005) (1)
441: Pathologic Variables and Recurrence Rates as Related to Obesity and Race in Men with Prostate Cancer Undergoing Radical Prostatectomy (2004) (1)
EFFECTS OF AGE, HEALTH-RELATED QUALITY OF LIFE, AND EDUCATION LEVEL ON MANAGEMENT AFTER BIOCHEMICAL FAILURE WITH WATCHFUL WAITING VERSUS HORMONAL THERAPY IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY (2008) (1)
Management Options for Gynaecomastia and Breast Pain Associated with Nonsteroidal Antiandrogen Therapy (2012) (1)
Cancer-specific survival following radical prostatectomy or radiation therapy and short course hormonal therapy in men with localized, unfavorable-risk prostate cancer. (2006) (1)
Testicular tumors: the military experience. (1978) (1)
Delaying metastatic disease progression in locally advanced disease - Results from the Early Prostate Cancer program at a median follow-up of 7.4 years. (2006) (1)
280: Quantitative Features of a Common TMPRSS2-ERG Fusion Transcript in Prostate Cancer (2007) (1)
181 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: Analysis at a median follow-up of 5.4 years (2004) (1)
Abstract 623: Evaluation of a multiplex biomarker assay for the detection of prostate cancer cells in urine (2015) (1)
The Evolving Role of Imaging in Identification and Management of Prostate Cancer (2006) (1)
Perioperative complications of radical retropubic prostatectomy. (2005) (1)
674: The Bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at Median 5.7 Years' Follow-Up (2005) (1)
Bicalutamide 150 mg in Addition to Standard Care Delays Progression to Bone Metastases in Patients with Locally Advanced Prostate Cancer: Analyses From the Second Analysis of the Early Prostate Cancer Program (2005) (1)
Structure and expression of TMPRSS2-ERG splice variants in prostate cancer (2008) (1)
The clinical significance of a PSA nadir > 0.2 to patients with a rising post-operative or post-radiation PSA treated with androgen deprivation (2005) (1)
EVALUATION OF REVERSE TRANSCRIPTASE (RT)-POLYMERASE CHAIN REACTION (PCR)-PROSTATE SPECIFIC ANTIGEN (PSA) ASSAY IN EPITHELIAL CELLS ISOLATED FROM PERIPHERAL BLOOD OF PROSTATE CANCER (CaP) PATIENTS (1999) (1)
A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients (2004) (1)
Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: Results from the Early Prostate Cancer program. (2006) (1)
Abstract 140: LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men (2016) (1)
MP02-05 AUTOANTIBODIES AGAINST ERG, AMACR, C-MYC AND HERV GAG IN THE SERA OF PROSTATE CANCER PATIENTS: POTENTIAL USE IN DIAGNOSIS/PROGNOSIS (2016) (1)
152 ALL-CAUSE MORTALITY AMONG MILITARY HEALTH CARE BENEFICIARIES WITH PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE (2011) (1)
Decade-long Trends in Prostate Cancer Incidence and Mortality in Poland, 1999–2012 (2018) (1)
ETS RELATED GENE (ERG) DRIVEN ANDROGEN RECEPTOR AGGREGATION IS A KEY REGULATOR OF ENDOPLASMIC STRESS AND CELL SURVIVAL DURING PROSTATE CARCINOGENESIS: MP87‐19 (2017) (0)
Follow-up care for survivors of breast and prostate cancer: primary care physicians must be up-to-date on the new long-term adjuvant treatment options and know how best to minimize long-term effects, particularly on bone health (2005) (0)
MP41-01 HIGHER GRADE PROSTATE CANCER STRATIFICATION BY ERG ONCOPROTEIN AND SPINK1 EXPRESSION IN CAUCASIAN AMERICAN AND AFRICAN AMERICAN MEN (2014) (0)
Anaplastic seminoma: an analysis of 77 patients. [Treatment effectiveness and complications] (1979) (0)
446: Contemporary Experience with Hormone Refractory Prostate Cancer (HRPC-Stage D3) in the PSA-Era: Report from the DOD CPDR National Database (2004) (0)
Epithelial cell transcriptome of poorly and moderately differentiated prostate cancers (2006) (0)
229: Frequent Overexpression of ETS-related Gene (ERG) in Prostate Cancer Transcriptome Reveals its Diagnostic and Prognostic Potential (2005) (0)
Abstract A35: Increased expression of PCGEM1 lncRNA in prostate cancer of African American men (2016) (0)
Tumor Markers in Hydrocele Fluids of Patients With Benign and Malignant Scrotal Diseases: Editorial Comment (1997) (0)
Abstract 1936: The increased frequency of ERG oncoprotein expression in high grade prostate cancers in Caucasian American in comparison to African American men. (2013) (0)
Abstract 2614: Distinguished features of ERG oncoprotein expression among matched cohorts of African-American and Caucasian-American prostate cancer patients (2012) (0)
Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues. (2008) (0)
815: Does Obesity Increase Intraoperative and Postoperative Complications in Men Undergoing Radical Prostatectomy? (2004) (0)
641: Development of Prostate Tissue and/or Prostate Cancer Specific Gene Panel for Defining Circulating Prostate Epithelial Cells (CPECS) (2004) (0)
Abstract 3595: A panel of serum proteins, metabolite and lipid for prognosing prostate cancer progression (2018) (0)
Abstract A86: Prostate cancer risk allele specific for African descent correlates with pathologic stage at prostatectomy (2009) (0)
Abstract C023: Annexin A2 expression level correlates with adverse pathology and disease progression in prostate cancer (2020) (0)
Abstract 3448: ERG-negative index tumor status combined with obesity predict prostate cancer progression in Caucasian American prostate cancer patients (2016) (0)
Association of expression of ERG oncoprotein with development of disease recurrence and prostate cancer-specific mortality. (2012) (0)
979: Prostate Cancer Associated Androgen Receptor Mutation Promotes Cell Growth and Abrogates P53 Mediated Apoptosis (2006) (0)
PROSTATE TUMOR-STROMAL GENE EXPRESSION SIGNATURES IN WELL AND POORLY DIFFERENTIATED CANCERS (2008) (0)
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer (2020) (0)
Abstract 4007: Defining the role of ERG-mediated repression of HPGD in prostate tumorigenesis (2011) (0)
Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated (2000) (0)
Re: Antibody-Based Detection of ERG Rearrangement- Positive Prostate Cancer Park K, Tomlins SA, Mudaliar KM, et al (2011) (0)
MP37-17 DISTINCT EXPRESSION FEATURES OF PMEPA1 AND ITS ISOFORM STAG1 IN PROSTATE CANCER (2015) (0)
DEVELOPMENT OF A PROSTATE CANCER GENE EXPRESSION PANEL TO ADDRESS RACIAL DIFFERENCES OF MOLECULAR ALTERATIONS IN PROSTATE CANCER: MP33‐12 (2017) (0)
MP-15.14: Elevated Secreted Protein, Acidic, and Rich in Cysteine (SPARC) Expression in Prostate Cancer Correlates with Tumor Metastasis after Radical Prostatectomy (2009) (0)
Prostate cancer diagnosis. (1995) (0)
MP28-15 SERUM BIOMARKERS FOR PROGNOSIS OF DISEASE PROGRESSION IN PROSTATE CANCER USING MULTI-OMICS (2019) (0)
217 FREQUENCY AND CLINICOPATHOLOGICAL FEATURES OF DOMINANT ANTERIOR PROSTATIC CARCINOMAS (2013) (0)
ELEVATED C-MYC EXPRESSION IN PRIMARY PROSTATE TUMOR PREDICTS BIOCHEMICAL RECURRENCE (2009) (0)
1408: The Importance of Prostate Cancer Tumor Volume in Men with Pathologically Organ Confined Disease (2007) (0)
Abstract 2830: Secreted protein acidic and rich in cysteine antigen and autoantibodies in sera of prostate cancer patients: Potential use in diagnosis /prognosis (2017) (0)
Prognostic factors in testicular tumors. (1988) (0)
Abstract 352: ERG protein is a marker for vascular tumors and prostatic adenocarcinoma (2011) (0)
1 Multidisciplinary Team Approach for Prostate Cancer (2008) (0)
MP78-08 RACIAL/ETHNIC PATTERNS IN THE PERFORMANCE OF MULTIPLEX URINE ERG AND PCA3 FOR PROSTATE CANCER DETECTION (2014) (0)
MP66-05 A NOVEL DELETION OF THE LSAMP GENE LOCUS ASSOCIATES WITH RAPID PROGRESSION OF PROSTATE CANCER AMONG AFRICAN AMERICAN MEN (2016) (0)
Comment on: Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Authors'reply (2004) (0)
534: Evaluation of New Prostate Cancer Specific Secretory Protein Panel in Serum of Prostate Cancer Patients (2007) (0)
Abstract A013: Prostate cancer gene expression panel to address racial differences of molecular alterations in prostate cancer (2018) (0)
Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC). (2016) (0)
1304 DOWN-REGULATION OF ERG IN PROSTATE CANCER CELLS ACTIVATES EPITHELIAL CELL DIFFERENTIATION (2010) (0)
Abstract 1206: Evaluation of androgen receptor function index (ARFI) in prostate cancer. (2013) (0)
1490: Correlation of one Core Positive Biopsy for Cancer with Index or Total Tumor Volume Less than 0.5CC in Prostatectomy Specimens (2005) (0)
226: Gene Expression / Biochemical Pathway Signatures of Prostate Cancer Cells of Patients with High Risk and Moderate Risk Progression of Disease (2005) (0)
CLINICAL UROLOGY: LETTER TO THE EDITORRE: DETECTION OF CIRCULATING PROSTATE SPECIFIC ANTIGEN EXPRESSING PROSTATIC CELLS IN THE BONE MARROW OF RADICAL PROSTATECTOMY PATIENTS BY SENSITIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (2000) (0)
Editorial: Some Aspects of Prostate Cancer (1996) (0)
Abstract 4649: Development of an ethnicity informed gene expression panel with potential to improve prostate cancer diagnosis (2017) (0)
MP41-05 DELINEATION OF THE BIOLOGICAL LINK BETWEEN THE ERG SPLICE VARIANT, ERG8, AND ITS PROGNOSTIC FEATURES (2014) (0)
470: Changing Face of Prostate Cancer in the PSA-Era: Results from the CPDR National Database (2004) (0)
2285: Clinical Predictors of Bone Metastasis Following Definitive Radiation Therapy for Prostate Cancer (2006) (0)
Support of the Center for Prostate Disease Research at Walter Reed Army Institute of Research. (1994) (0)
SELECTIVE TRANSCRIPTIONAL DOWN-REGULATION OF THE WILD TYPE TMPRSS2 ALLELE IN PROSTATE TUMOR CELLS HARBORING TMPRSS2-ERG FUSION (2008) (0)
Bicalutamide 150 mg as adjuvant to radiotherapy significantly increases progression-free survival in early prostate cancer (2003) (0)
Emerging role of adjuvant hormonal therapy. Discussion (2002) (0)
669: Effects and Mechanisms of Frequent Downregulation of Lactotransferrin (LTF) in Prostate Cancer (2007) (0)
Abstract 2016: Evaluation of prostate cancer biomarkers and therapeutic targets in FFPE specimens using the NanoString platform (2015) (0)
Abstract 1920: Variation of ERG oncoprotein expression in prostate cancer patients with different ethnicities. (2013) (0)
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (2020) (0)
Abstract 4645: A serum multiomics signature for enhancing prostate cancer diagnosis and prognosis (2017) (0)
PROSTATE CANCER IN AMERICAN INDIANS, NEW MEXICO, 1969 TO 1994: EDITORIAL COMMENT (1998) (0)
PMEPA1-AR DEGRADATION PATHWAY: A NEW MECHANISM FOR THE REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER (2009) (0)
PD-07.03 (2006) (0)
235: Evaluation of Serum Seldi-Tof Proteomic Information and Tumor Volume in Prostate Cancer Patients (2005) (0)
Abstract 4504: Androgen receptor aggregation is a key regulator of endoplasmic reticulum stress and cell survival in ETS-related gene driven prostate carcinogenesis (2017) (0)
MP41-02 CLINICAL AND PATHOLOGIC CHARACTERIZATION OF ERG EXPRESSION AND TESTOSTERONE IN AFRICAN AMERICANS (2014) (0)
471 DISTINGUISHING FEATURES OF ERG ONCOPROTEIN EXPRESSION AMONG MATCHED COHORTS OF AFRICAN-AMERICAN AND CAUCASIAN-AMERICAN PROSTATE CANCER PATIENTS (2012) (0)
Reply to A. Tubaro and C. De Nunzio (2004) (0)
Bicalutamide (‘Casodex’) 150 Mg as adjuvant to radical prostatectomy significantly increases progression-free survival in early prostate cancer: Evidence from a new analysis (2003) (0)
Lactotransferrin: A frequent expression downregulation in prostate cancer (2006) (0)
MP02-11 A NANOSTRING PLATFORM BASED ASSAY DEFINES ABSENCE OF ERG FUSION OR ATTENUATED ANDROGEN RECEPTOR FUNCTION INDEX (ARFI) AS EARLY INDICATORS OF BIOCHEMICAL RECURRENCE IN A SUBSET OF LOW GRADE PROSTATE CANCER (2016) (0)
Melanomas that defy clinical recognition. (1992) (0)
ASSOCIATION OF GERMLINE GENETIC VARIANTS WITH TMPRSS2‐ERG FUSION STATUS IN PROSTATE CANCER: MP87‐18 (2017) (0)
Evidence to Support that Serial Screening Decreases Prostate Cancer-Specific Mortality (2005) (0)
540: Elevated Secreted Protein, Acidic, and Rich in Cysteine (SPARC) MRNA Expression in Neoplastic Prostate Epithelial Cells Correlates with PSA Recurrence after Radical Prostatectomy (2007) (0)
Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1 (2000) (0)
2130 ROBUST ERG ONCOPROTEIN EXPRESSION IN PROSTATE CANCER: POTENTIAL FOR ERG BASED STRATIFICATION (2010) (0)
541: Magnetic Resonance Microscopy of Radical Prostatectomies at 7 Tesla (2007) (0)
Five Year PSA-Failure Rates for Prostate Cancer Patients Treated with Dose-Escalated IMRT (2011) (0)
CORRELATION OF PRE-BIOPSY PSA LEVELS WITH TUMOR VOLUME AND SURGICAL MARGIN STATUS IN STAGE T1C PATIENTS (1999) (0)
Abstract 30: ERG oncoprotein expression in prostate cancer: Potential for ERG-based stratification (2010) (0)
MP09-17 THE NATURAL HISTORY OF METASTASIS AS A FUNCTION OF PSADT IN A SURGICALLY-TREATED PATIENT COHORT EXPERIENCING BIOCHEMICAL RELAPSE (2016) (0)
MP90-14 DISTINCT BIOLOGICAL FEATURES OF PROSTATE TUMORS IN THE CONTEXT OF RACE/ETHNICITY AND ERG STATUS (2016) (0)
Some aspects of prostate cancer. (1996) (0)
1429 IN VIVO READOUT OF ANDROGEN RECEPTOR (AR) FUNCTIONAL STATUS IN PRIMARY TUMORS FOR PATIENT STRATIFICATION (2010) (0)
1666: Serum Proteomic Profiling Using Seldi-Tof for Prostate Cancer Diagnosis (2004) (0)
OF ERG FUSION OR ATTENUATED ANDROGEN RECEPTOR FUNCTION INDEX (ARFI) AS EARLY INDICATORS OF BIOCHEMICAL RECURRENCE IN A SUBSET OF LOW GRADE PROSTATE CANCER (2016) (0)
STRUCTURE‐ACTIVITY RELATIONSHIP STUDIES OF ERGI‐USU, A HIGHLY SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS: MP87‐14 (2017) (0)
Bicalutamide (‘casodex’) 150 mg as adjuvant to radiotherapy in localised or locally advanced prostate cancer (2001) (0)
Comparison of ERG oncoprotein expression among matched cohorts of African American and Caucasian American patients with prostate cancer. (2012) (0)
863: Racial Difference in Location, Number and Volume of Prostate Cancerbased on 3-Dimensional Reconstructed Radical Prostatectomy Specimens (2004) (0)
Abstract 4963:ERGexpression levels reflect functional status of androgen receptor in prostate cancer (2010) (0)
Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis (2020) (0)
ERG REGULATES C-MYC AND ABROGATES DIFFERENTIATION IN PROSTATE CANCER (2009) (0)
Abstract B42: Development of a urine exosome-based prostate cancer gene expression panel to address racial differences in prostate cancer (2018) (0)
1266: A Multi-Center Study: Safety, Efficacy and Patient Satisfaction Results of the Two-Piece Ambicor™ Inflatable Penile Prosthesis (IPP) (2005) (0)
148 PROSTATE CANCER IN MEN ≥70, INDOLENT OR AGGRESSIVE: CLINICOPATHOLOGIC ANALYSIS AND OUTCOMES (2011) (0)
1446 DOES PROSTATE TUMOR PROXIMITY TO SURGICAL MARGIN IN PT2 DISEASE CORRELATE WITH TIME TO BIOCHEMICAL RECURRENCE OR ALL-CAUSE MORTALITY? (2011) (0)
1102: Gene Expression Signatures in Benign and Malignant Epithelial Cells of Prostate Cancer Patients with “Aggressive” and “Non-Aggressive” Disease (2004) (0)
959 IMMUNOHISTOCHEMICAL EXPRESSION OF ERG ONCOPROTEIN IS ASSOCIATED WITH DEVELOPMENT OF LOCAL RECURRENCE AND PROSTATE CANCER-SPECIFIC DEATH IN MEN TREATED WITH RADICAL PROSTATECTOMY (2012) (0)
Abstract 1859: Potential impact on the biology and biomarker utility of ERG-typing in the context of ethnic differences of prostate cancer (2014) (0)
The association of a 17-gene genomic prostate score with adverse surgical pathology and recurrence following surgery for localized prostate cancer (PCa): A comparison of African American and Caucasian patients. (2015) (0)
CYTOLOGIC DETECTION OF CIRCULATING TUMOR CELLS IN LOW VOLUME PROSTATE CANCER (2009) (0)
Follow-up care for survivors of breast and prostate cancer (2005) (0)
245: Novel Telomerase-Immortalized Primary Prostate Epithelial Cell Lines Retain Biological Features of Benign and Cancerous Prostate Specimens (2006) (0)
MP61-10 SILENCING OF PMEPA1 IS ASSOCIATED WITH ACTIVATION OF AR SIGNALING IN HUMAN PROSTATE CANCER AND CASTRATION RESISTANT TUMOR GROWTH IN NUDE MOUSE (2015) (0)
1050: Pre- and Post-Surgery Factors Affecting the Outcomes of Patients with Intermediate Risk Prostate Cancer (2004) (0)
MP87-08 SYNTHESIS AND EVALUATION OF STRUCTURE-ACTIVITY RELATIONSHIP OF DERIVATIVES OF A SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS (2018) (0)
Abstract 3004: Functional analysis of ERG splice variants and their effect on c-myc expression in prostate cancer. (2013) (0)
PD42-10 NUCLEAR GRADE PREDICTS PROSTATE CANCER OUTCOMES AMONG RADICAL PROSTATECTOMY PATIENTS (2016) (0)
UP-02.195 Clinicopathological Correlation of ERG Protein Expression in Single Focus Prostate Cancer (2011) (0)
1193: Quantitative Gene Expression Ratios of Androgen Receptor MRNA in Benign and Neoplastic Prostate Epithelial Cells Correlate with PSA Recurrence after Radical Prostatectomy (2006) (0)
Expression during Prostate Cancer Progression Exhibits Cell Growth Inhibitory Function and Decreased PMEPA 1 , an Androgen-regulated NEDD 4-binding Protein (2003) (0)
UP-1.097: Osteoblast-Specific Factor 2 as a Putative High-Grade Tumor-Associated Stromal Marker for Prostate Cancer: Identification Through Microarray Technology (2009) (0)
1303 EFFECT OF ONCOGENIC ACTIVATION OF ERG ON PROSTAGLANDIN SIGNALING PATHWAYS IN PROSTATE CANCER CELLS (2010) (0)
Abstract 4175: ERG oncogenic activation leads to the endoplasmic reticulum stress and cell survival mechanisms (2016) (0)
Prostate-specific antigen velocity and the odds of detecting gleason 8 to 10 prostate cancer at biopsy. (2006) (0)
PSA doubling time (PSADT) ≤6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET). (2016) (0)
231: Predicting Overall Survival among Prostate Cancer Patients Treated with Primary Androgen Deprivation Therapy Versus Expectant Management (2007) (0)
Prostate cancer. (1995) (0)
TMPRSS2-ERGfusion transcript has diagnostic and prognostic potential in prostate cancer patients (2006) (0)
1402: Predicting Biochemical Failure in Men with Low Volume (< 0.5CC) Prostate Cancer Treated by Radical Prostatectomy (2007) (0)
MP61-16 ETHNIC DIFFERENCES OF ERG ONCOGENIC ALTERATION IN PROSTATE CANCER: CONCLUSIONS FROM 1139 WHOLE MOUNT PROSTATES (2015) (0)
RELATIVE FREQUENCIES OF ETV1 AND ERG OVEREXPRESSION IN PROSTATE CANCER (2008) (0)
Prostate Cancer A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-risk Prostate Cancer (2015) (0)
MP04-18 LONGITUDINAL REGRET AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING TREATMENT FOR LOW- AND INTERMEDIATE-RISK PROSTATE CANCER (2016) (0)
A NEW CELL LINE EXPRESSING A NOVEL TYPE OF TMPRSS2- ERG GENE FUSION DERIVED FROM PRIMARY TUMORS OF FAMILIAL PROSTATE CANCER PATIENT (2008) (0)
Comparison of ERG oncoprotein expression among matched cohorts of African American and Caucasian American patients with prostate cancer. (2012) (0)
MP84-10 ERG INDUCES ENDOPLASMIC RETICULUM STRESS (ER) AND UNFOLDED PROTEIN RESPONSE (UPR) TO INITIATE PROSTATE CANCER CARCINOGENESIS (2016) (0)
425: Quantitative Expression Profile of PSGR in Prostatic Epithelial Cells of Benign and Malignant Prostate (2004) (0)
1061: Bicalutamide 150 mg for Early non-Metastatic Prostate Cancer in Patients Who Would Otherwise Undergo Watchful Waiting: Latest Results at a Median 5.4 Years' Follow-up (2004) (0)
UP-02.65: The relationship of preoperative PSA levels to prostatic weight and tumor size (2006) (0)
1318 AGE-ASSOCIATED GENE-EXPRESSION SIGNATURES IN NON-FAMILIAL PROSTATE CANCER (2012) (0)
821: Intermediate Results of Ferromagnetic Thermal Ablation for Radiation Failure Local Recurrence of Prostate Cancer (2004) (0)
MP66-12 A NOVEL CELL BASED MULTIPLEX BIOMARKER ASSAY FOR PROSTATE CANCER DETECTION IN URINE (2015) (0)
ERG protein expression in prostate and vascular tumors: A potential for ERG-based stratification. (2011) (0)
Clinical evolution of cystic teratoma during treatment with combination chemotherapy. (1986) (0)
Racial/ethnic variation in a common genetic alteration in prostate cancer. (2015) (0)
MP61-20 EVALUATION OF ANDROGEN RECEPTOR FUNCTION IN AFRICAN AMERICAN AND CAUCASIAN AMERICAN PROSTATE CANCERS (2015) (0)
MP-10.20: Follow-up on patients with small prostate cancer following radical prostatectomy at Walter Reed Army Medical Center (2006) (0)
UNIFOCAL AND MULTIFOCAL PROSTATE CANCER: A COMPARISON OF CLINICOPATHOLOGIC FEATURES (2009) (0)
224 ACTIVE SURVEILLANCE FOR YOUNG PROSTATE CANCER PATIENTS (2013) (0)
Abstract 4958: Immunobiomarkers: novel autoantibody panel comprising oncogenic ERG, C-MYC, AMACR and HERV-K Gag for the detection of prostate cancer (2016) (0)
944 ALKALINE PHOSPHATASE KINETICS AND THE RISK OF BONE METASTASES IN MEN UNDERGOING ANDROGEN DEPRIVATION THERAPY (2012) (0)
435: Lactotransferrin: A Frequent Expression Down-Regulation in Prostate Cancer (2006) (0)
1106: Quantitative Expression Characteristics of a Panel of Prostate Cancer Genes in Matched Benign and Neoplastic Prostate Cells of Patients with “Aggressive” and “Non-Aggressive” Cancer (2004) (0)
445: Prostate Cancer Mortality After Radical Prostatectomy or Radiation Therapy in Men with Clinically Localized Prostate Cancer (2004) (0)
UP-02.170 Does Prostate Tumor Proximity to Surgical Margin in pT2 Disease Correlate with Biochemical Recurrence or All-cause Mortality? (2011) (0)
Mechanism of prostate cancer progression in androgen-independent variants of LAPC4 cells with or without androgen receptor (2008) (0)
Abstract 4679: Silencing of PMEPA1, a NEDD4 E3 ubiquitin ligase binding protein, stabilizes androgen receptor and confers resistance to AR inhibitors (2015) (0)
Abstract 2772: Recurrent alterations of the TenascinC in highly aggressive neuroendocrine sub-type of prostate cancer (2019) (0)
1588: The Bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at 7.7 Years' Median Follow-Up (2006) (0)
MP66-06 OPTIMIZATION OF NANOSTRING PLATFORM FOR EVALUATION OF PROSTATE CANCER BIOMARKERS AND THERAPEUTIC TARGETS IN FFPE SPECIMENS (2015) (0)
Abstract 4341: Distinct expression of PMEPA1 and its isoform, STAG1 in prostate cancer (2015) (0)
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods (2015) (0)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (0)
TAILORING PRIMARY THERAPY FOR PROSTATE CANCER BASED ON HEALTH-RELATED QUALITY OF LIFE (2009) (0)
Abstract 1818: Analytical platform evaluation for quantification of ERG oncoprotein in prostate cancer using protein and mRNA detection methods (2015) (0)
1596: Choices for Definitive Treatment of Early-Stage Prostate Cancer: Results from the Compare Registry (2006) (0)
7. RIU0472_07-31.qxd (2010) (0)
ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH ERG FUSION STATUS IN PROSTATE CANCER: MP70‐10 (2018) (0)
NOMOGRAM BASED ON SEXTANT POSITIVE BIOPSY CORES, GLEASON SUM AND PRE-BIOPSY PSA TO PREDICT ORGAN CONFINEMENT IN RADICAL PROSTATECTOMY PATIENTS-A CENTER FOR PROSTATE DISEASE RESEARCH (CPDR) MULTI-CENTER STUDY (1999) (0)
MP41-15 EVALUATION OF ANDROGEN RECEPTOR FUNCTION IN PROSTATE CANCER (2014) (0)
PROLIFERATIVE ACTIVITY IN PROSTATIC INTRAEPITHELIAL NEOPLASIA OF PATIENTS TREATED WITH ANDROGEN BLOCKADE (1999) (0)
Abstract 1290: Association of common genetic variants withTMPRSS2 ERGfusion status in prostate cancer (2017) (0)
858: A Comparison of Two Grading Systems in Predicting Stage (2004) (0)
Low risk prostate cancer in men > 70 years old: to treat or not to treat (2011) (0)
352 THE ROLES OF RACE/ETHNICITY AND BODY MASS INDEX ON PROSTATE CANCER BIOCHEMICAL RECURRENCE AND ALL-CAUSE MORTALITY (2012) (0)
Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients (2012) (0)
Abstract 1929: A sensitive cell-based assay for the evaluation of prostate cancer cells in urine. (2013) (0)
Abstract C18: ERG-focused evaluations of prostate cancer of African American men and its potential impact on utility in biomarker development and in enhanced personalized medicine (2014) (0)
207: Management of Prostate-specific Antigen (PSA) Recurrence after Initial Definitive Local Therapy for Prostate Cancer: Updated Results from the Compare Registry (2007) (0)
Random Bone Marrow Biopsy and Immunoperoxidase Staining in Stage D 0 Prostate Cancer (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David G. Mcleod?

David G. Mcleod is affiliated with the following schools:

University of Southern California
Uniformed Services University of the Health Sciences
Duke University

David G. Mcleod's Academic­Influence.com Rankings

David G. Mcleod's Degrees

Why Is David G. Mcleod Influential?

David G. Mcleod's Published Works

Published Works

What Schools Are Affiliated With David G. Mcleod?

David G. Mcleod's AcademicInfluence.com Rankings